{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,3]],"date-time":"2026-11-03T17:11:43Z","timestamp":1793725903249,"version":"4.6.1"},"reference-count":68,"publisher":"Elsevier BV","issue":"5","license":[{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,10,1]],"date-time":"2023-10-01T00:00:00Z","timestamp":1696118400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,7,13]],"date-time":"2023-07-13T00:00:00Z","timestamp":1689206400000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CMRPG3K1501\/2"],"award-info":[{"award-number":["CMRPG3K1501\/2"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100004606","name":"Chang Gung Medical Foundation","doi-asserted-by":"publisher","award":["CORPG3J0421"],"award-info":[{"award-number":["CORPG3J0421"]}],"id":[{"id":"10.13039\/501100004606","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedical Journal"],"published-print":{"date-parts":[[2023,10]]},"DOI":"10.1016\/j.bj.2023.100633","type":"journal-article","created":{"date-parts":[[2023,7,17]],"date-time":"2023-07-17T20:53:40Z","timestamp":1689627220000},"page":"100633","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":29,"title":["Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances"],"prefix":"10.1016","volume":"46","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3834-2754","authenticated-orcid":false,"given":"Angel","family":"Chao","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ren-Chin","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiao-Yun","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ting-Chang","family":"Chang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chyong-Huey","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"7","key":"10.1016\/j.bj.2023.100633_bib1","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1136\/jclinpath-2015-203551","article-title":"Neuroendocrine tumours in rare sites: differences in nomenclature and diagnostics-a rare and ubiquitous histotype","volume":"69","author":"Guadagno","year":"2016","journal-title":"J Clin Pathol"},{"issue":"Pt 1","key":"10.1016\/j.bj.2023.100633_bib2","first-page":"273","article-title":"Carcinoid tumors of the cervix","volume":"14","author":"Albores-Saavedra","year":"1979","journal-title":"Pathol Annu"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib3","first-page":"34","article-title":"Terminology of endocrine tumors of the uterine cervix: results of a workshop sponsored by the College of American Pathologists and the National Cancer Institute","volume":"121","author":"Albores-Saavedra","year":"1997","journal-title":"Arch Pathol Lab Med"},{"issue":"6","key":"10.1016\/j.bj.2023.100633_bib4","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1177\/1066896916643385","article-title":"Neuroendocrine carcinoma of the cervix: review of a series of cases and correlation with outcome","volume":"24","author":"Ganesan","year":"2016","journal-title":"Int J Surg Pathol"},{"issue":"6","key":"10.1016\/j.bj.2023.100633_bib5","doi-asserted-by":"crossref","first-page":"986","DOI":"10.1136\/ijgc-2019-000504","article-title":"Updates and management algorithm for neuroendocrine tumors of the uterine cervix","volume":"29","author":"Salvo","year":"2019","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.bj.2023.100633_bib6","first-page":"586","article-title":"Evaluation of histologic, morphometric, and immunohistochemical criteria in the differential diagnosis of small cell carcinomas of the cervix with particular reference to human papillomavirus types 16 and 18","volume":"4","author":"Ambros","year":"1991","journal-title":"Mod Pathol"},{"issue":"4","key":"10.1016\/j.bj.2023.100633_bib7","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/PAS.0b013e3181d1d457","article-title":"An immunohistochemical study of cervical neuroendocrine carcinomas: neoplasms that are commonly TTF1 positive and which may express CK20 and P63","volume":"34","author":"McCluggage","year":"2010","journal-title":"Am J Surg Pathol"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib8","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.anndiagpath.2012.01.009","article-title":"Spectrum of neuroendocrine carcinomas of the uterine cervix, including histopathologic features, terminology, immunohistochemical profile, and clinical outcomes in a series of 50 cases from a single institution in India","volume":"17","author":"Rekhi","year":"2013","journal-title":"Ann Diagn Pathol"},{"issue":"2","key":"10.1016\/j.bj.2023.100633_bib9","doi-asserted-by":"crossref","first-page":"247","DOI":"10.1016\/j.ygyno.2016.02.008","article-title":"Natural history and outcome of neuroendocrine carcinoma of the cervix","volume":"141","author":"Margolis","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bj.2023.100633_bib10","doi-asserted-by":"crossref","first-page":"833","DOI":"10.1002\/1878-0261.12962","article-title":"Genomic characterization of small cell carcinomas of the uterine cervix","volume":"16","author":"Schultheis","year":"2022","journal-title":"Mol Oncol"},{"issue":"2","key":"10.1016\/j.bj.2023.100633_bib11","doi-asserted-by":"crossref","first-page":"422","DOI":"10.1016\/j.ygyno.2017.12.001","article-title":"A systematic review and meta-analysis on the attribution of human papillomavirus (HPV) in neuroendocrine cancers of the cervix","volume":"148","author":"Castle","year":"2018","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bj.2023.100633_bib12","doi-asserted-by":"crossref","first-page":"134","DOI":"10.1016\/j.pvr.2018.03.005","article-title":"Contribution of Human papillomavirus in neuroendocrine tumors from a series of 10,575 invasive cervical cancer cases","volume":"5","author":"Alejo","year":"2018","journal-title":"Papillomavirus Res"},{"key":"10.1016\/j.bj.2023.100633_bib13","doi-asserted-by":"crossref","first-page":"342","DOI":"10.1038\/nrc798","article-title":"Papillomaviruses and cancer: from basic studies to clinical application","volume":"2(5)","author":"zur Hausen","year":"2002","journal-title":"Nat Rev Cancer"},{"issue":"7645","key":"10.1016\/j.bj.2023.100633_bib14","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1038\/nature21386","article-title":"Integrated genomic and molecular characterization of cervical cancer","volume":"543","year":"2017","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.bj.2023.100633_bib15","doi-asserted-by":"crossref","first-page":"750","DOI":"10.1097\/PAS.0000000000001042","article-title":"Next-generation sequencing reveals recurrent somatic mutations in small cell neuroendocrine carcinoma of the uterine cervix","volume":"42","author":"Xing","year":"2018","journal-title":"Am J Surg Pathol"},{"issue":"6","key":"10.1016\/j.bj.2023.100633_bib16","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0234505","article-title":"Comparative genomics of high grade neuroendocrine carcinoma of the cervix","volume":"15","author":"Hillman","year":"2020","journal-title":"PLoS One"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib17","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1016\/j.ygyno.2016.04.001","article-title":"Sequencing of mutational hotspots in cancer-related genes in small cell neuroendocrine cervical cancer","volume":"141","author":"Frumovitz","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib18","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/j.ygyno.2021.04.019","article-title":"The next generation sequencing of cancer-related genes in small cell neuroendocrine carcinoma of the cervix","volume":"161","author":"Pei","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"5","key":"10.1016\/j.bj.2023.100633_bib19","doi-asserted-by":"crossref","first-page":"8095","DOI":"10.18632\/oncotarget.14098","article-title":"Cervical small cell neuroendocrine tumor mutation profiles via whole exome sequencing","volume":"8","author":"Cho","year":"2017","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.bj.2023.100633_bib20","doi-asserted-by":"crossref","first-page":"299","DOI":"10.1097\/PAI.0000000000000884","article-title":"Molecular profiling reveals limited targetable biomarkers in neuroendocrine carcinoma of the cervix","volume":"29","author":"Cimic","year":"2021","journal-title":"Appl Immunohistochem Mol Morphol"},{"key":"10.1016\/j.bj.2023.100633_bib21","doi-asserted-by":"crossref","first-page":"752453","DOI":"10.3389\/fonc.2021.752453","article-title":"PD-L1, mismatch repair protein, and NTRK immunohistochemical expression in cervical small cell neuroendocrine carcinoma","volume":"11","author":"Chen","year":"2021","journal-title":"Front Oncol"},{"issue":"9","key":"10.1016\/j.bj.2023.100633_bib22","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1016\/j.jtho.2021.02.009","article-title":"Efficacy and safety of rovalpituzumab tesirine compared with topotecan as second-line therapy in DLL3-high SCLC: results from the phase 3 TAHOE study","volume":"16","author":"Blackhall","year":"2021","journal-title":"J Thorac Oncol"},{"key":"10.1016\/j.bj.2023.100633_bib23","article-title":"Unique genomic landscape of high-grade neuroendocrine cervical carcinoma: implications for rethinking current treatment paradigms","volume":"4","author":"Eskander","year":"2020","journal-title":"JCO Precis Oncol"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib24","doi-asserted-by":"crossref","first-page":"100","DOI":"10.1038\/s41379-018-0122-7","article-title":"Insulinoma-associated protein 1 (INSM1) is a sensitive and highly specific marker of neuroendocrine differentiation in primary lung neoplasms: an immunohistochemical study of 345 cases, including 292 whole-tissue sections","volume":"32","author":"Mukhopadhyay","year":"2019","journal-title":"Mod Pathol"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib25","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.3802\/jgo.2023.34.e1","article-title":"Immunosensitivity and specificity of insulinoma-associated protein 1 (INSM1) for neuroendocrine neoplasms of the uterine cervix","volume":"34","author":"Kuji","year":"2023","journal-title":"J Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.bj.2023.100633_bib26","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1016\/j.ygyno.2016.11.020","article-title":"A new marker, insulinoma-associated protein 1 (INSM1), for high-grade neuroendocrine carcinoma of the uterine cervix: analysis of 37 cases","volume":"144","author":"Kuji","year":"2017","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib27","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1016\/j.ygyno.2016.12.003","article-title":"Neuroendrocrine tumors of the uterine cervix: a therapeutic challenge for gynecologic oncologists","volume":"144","author":"Gadducci","year":"2017","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.bj.2023.100633_bib28","series-title":"NCCN guidelines: cervical blocks","year":"2022"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib29","doi-asserted-by":"crossref","first-page":"468","DOI":"10.1016\/j.ygyno.2015.03.015","article-title":"Primary surgery versus primary radiation therapy for FIGO stages I-II small cell carcinoma of the uterine cervix: a retrospective Taiwanese Gynecologic Oncology Group study","volume":"137","author":"Chen","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bj.2023.100633_bib30","doi-asserted-by":"crossref","first-page":"347. e1","DOI":"10.1016\/j.ajog.2010.04.019","article-title":"Small cell carcinoma of the cervix: treatment and survival outcomes of 188 patients","volume":"203","author":"Cohen","year":"2010","journal-title":"Am J Obstet Gynecol"},{"issue":"10","key":"10.1016\/j.bj.2023.100633_bib31","doi-asserted-by":"crossref","first-page":"1484","DOI":"10.1016\/j.ejca.2011.12.014","article-title":"Primary treatment and prognostic factors of small cell neuroendocrine carcinoma of the uterine cervix: a Taiwanese Gynecologic Oncology Group study","volume":"48","author":"Wang","year":"2012","journal-title":"Eur J Cancer"},{"issue":"9","key":"10.1016\/j.bj.2023.100633_bib32","doi-asserted-by":"crossref","first-page":"5355","DOI":"10.7314\/APJCP.2013.14.9.5355","article-title":"Prognostic impact of histology in patients with cervical squamous cell carcinoma, adenocarcinoma and small cell neuroendocrine carcinoma","volume":"14","author":"Intaraphet","year":"2013","journal-title":"Asian Pac J Cancer Prev APJCP"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib33","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1159\/000367920","article-title":"A multicenter study of the importance of systemic chemotherapy for patients with small-cell neuroendocrine carcinoma of the uterine cervix","volume":"79","author":"Lee","year":"2015","journal-title":"Gynecol Obstet Invest"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib34","first-page":"259","article-title":"Prognostic factors and treatment comparison in small cell neuroendocrine cervical carcinoma","volume":"35","author":"Yin","year":"2014","journal-title":"Eur J Gynaecol Oncol"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib35","doi-asserted-by":"crossref","first-page":"590","DOI":"10.1016\/j.ygyno.2008.11.010","article-title":"Small cell neuroendocrine carcinoma of the cervix: analysis of outcome, recurrence pattern and the impact of platinum-based combination chemotherapy","volume":"112","author":"Zivanovic","year":"2009","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib36","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1006\/gyno.2000.6118","article-title":"Multimodality therapy in early-stage neuroendocrine carcinoma of the uterine cervix","volume":"81","author":"Boruta","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.bj.2023.100633_bib37","doi-asserted-by":"crossref","first-page":"712","DOI":"10.1002\/(SICI)1097-0142(19980815)83:4<712::AID-CNCR12>3.0.CO;2-V","article-title":"Prognostic factors in surgically treated small cell cervical carcinoma followed by adjuvant chemotherapy","volume":"83","author":"Chang","year":"1998","journal-title":"Cancer"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib38","doi-asserted-by":"crossref","first-page":"71","DOI":"10.3892\/mco.2013.193","article-title":"A retrospective clinicopathological analysis of small-cell carcinoma of the uterine cervix","volume":"2","author":"Dongol","year":"2014","journal-title":"Mol Clin Oncol"},{"issue":"2","key":"10.1016\/j.bj.2023.100633_bib39","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1093\/annonc\/mdm465","article-title":"Prognostic factors in FIGO stage IB-IIA small cell neuroendocrine carcinoma of the uterine cervix treated surgically: results of a multi-center retrospective Korean study","volume":"19","author":"Lee","year":"2008","journal-title":"Ann Oncol"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib40","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1016\/j.ygyno.2019.09.018","article-title":"A multi-center retrospective study of neuroendocrine tumors of the uterine cervix: prognosis according to the new 2018 staging system, comparing outcomes for different chemotherapeutic regimens and histopathological subtypes","volume":"155","author":"Ishikawa","year":"2019","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib41","doi-asserted-by":"crossref","first-page":"32","DOI":"10.1006\/gyno.2001.6201","article-title":"Neuroendocrine cervical carcinoma: a diagnostic and therapeutic challenge","volume":"82","author":"Bermudez","year":"2001","journal-title":"Gynecol Oncol"},{"issue":"7","key":"10.1016\/j.bj.2023.100633_bib42","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S1470-2045(16)30066-3","article-title":"Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial","volume":"17","author":"Seiwert","year":"2016","journal-title":"Lancet Oncol"},{"issue":"19","key":"10.1016\/j.bj.2023.100633_bib43","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1056\/NEJMoa1606774","article-title":"Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer","volume":"375","author":"Reck","year":"2016","journal-title":"N Engl J Med"},{"issue":"21","key":"10.1016\/j.bj.2023.100633_bib44","doi-asserted-by":"crossref","first-page":"2460","DOI":"10.1200\/JCO.2015.64.8931","article-title":"Pembrolizumab in patients with advanced triple-negative breast cancer: phase Ib KEYNOTE-012 study","volume":"34","author":"Nanda","year":"2016","journal-title":"J Clin Oncol"},{"issue":"12","key":"10.1016\/j.bj.2023.100633_bib45","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/ni.2762","article-title":"A rheostat for immune responses: the unique properties of PD-1 and their advantages for clinical application","volume":"14","author":"Okazaki","year":"2013","journal-title":"Nat Immunol"},{"issue":"12","key":"10.1016\/j.bj.2023.100633_bib46","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1038\/modpathol.2015.108","article-title":"Enhanced expression of PD L1 in cervical intraepithelial neoplasia and cervical cancers","volume":"28","author":"Mezache","year":"2015","journal-title":"Mod Pathol"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib47","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.3892\/mmr.2017.6102","article-title":"Increased expression of PDL1 by the human papillomavirus 16 E7 oncoprotein inhibits anticancer immunity","volume":"15","author":"Liu","year":"2017","journal-title":"Mol Med Rep"},{"issue":"20","key":"10.1016\/j.bj.2023.100633_bib48","doi-asserted-by":"crossref","first-page":"1856","DOI":"10.1056\/NEJMoa2112435","article-title":"Pembrolizumab for persistent, recurrent, or metastatic cervical cancer","volume":"385","author":"Colombo","year":"2021","journal-title":"N Engl J Med"},{"issue":"36","key":"10.1016\/j.bj.2023.100633_bib49","doi-asserted-by":"crossref","first-page":"4035","DOI":"10.1200\/JCO.2017.74.5471","article-title":"Safety and efficacy of pembrolizumab in advanced, programmed death ligand 1-positive cervical cancer: results from the phase Ib KEYNOTE-028 trial","volume":"35","author":"Frenel","year":"2017","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2023.100633_bib50","doi-asserted-by":"crossref","first-page":"TPS6096","DOI":"10.1200\/JCO.2020.38.15_suppl.TPS6096","article-title":"ENGOT-cx11\/KEYNOTE-A18: a phase III, randomized, double-blind study of pembrolizumab with chemoradiotherapy in patients with high-risk locally advanced cervical cancer","volume":"38","author":"Lorusso","year":"2020","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.bj.2023.100633_bib51","doi-asserted-by":"crossref","DOI":"10.1136\/ijgc-2022-003370","article-title":"ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation","author":"Garcia-Duran","year":"2022","journal-title":"Int J Gynecol Cancer"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib52","doi-asserted-by":"crossref","first-page":"570","DOI":"10.1016\/j.ygyno.2020.05.682","article-title":"Phase II study of pembrolizumab efficacy and safety in women with recurrent small cell neuroendocrine carcinoma of the lower genital tract","volume":"158","author":"Frumovitz","year":"2020","journal-title":"Gynecol Oncol"},{"issue":"17","key":"10.1016\/j.bj.2023.100633_bib53","doi-asserted-by":"crossref","first-page":"1470","DOI":"10.1200\/JCO.18.01265","article-title":"Efficacy and safety of pembrolizumab in previously treated advanced cervical cancer: results from the phase II KEYNOTE-158 study","volume":"37","author":"Chung","year":"2019","journal-title":"J Clin Oncol"},{"issue":"5","key":"10.1016\/j.bj.2023.100633_bib54","doi-asserted-by":"crossref","first-page":"938","DOI":"10.1016\/j.tjog.2021.07.030","article-title":"Complete remission of advanced and recurrent cervical cancer with pembrolizumab treatment- 3 case reports","volume":"60","author":"Tung","year":"2021","journal-title":"Taiwan J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.bj.2023.100633_bib55","doi-asserted-by":"crossref","first-page":"631","DOI":"10.1634\/theoncologist.2016-0517","volume":"22","author":"Sharabi","year":"2017","journal-title":"Oncol"},{"key":"10.1016\/j.bj.2023.100633_bib56","doi-asserted-by":"crossref","first-page":"3","DOI":"10.1186\/s40661-017-0038-9","article-title":"Metastatic small cell neuroendocrine carcinoma of the cervix treated with the PD-1 inhibitor, nivolumab: a case report","volume":"4","author":"Paraghamian","year":"2017","journal-title":"Gynecol Oncol Res Pract"},{"issue":"21","key":"10.1016\/j.bj.2023.100633_bib57","doi-asserted-by":"crossref","first-page":"2369","DOI":"10.1200\/JCO.20.00793","article-title":"Pembrolizumab or placebo plus etoposide\u00a0and\u00a0platinum as first-line therapy for extensive-stage small-cell lung cancer: randomized, double-blind, phase III KEYNOTE-604 study","volume":"38","author":"Rudin","year":"2020","journal-title":"J Clin Oncol"},{"issue":"23","key":"10.1016\/j.bj.2023.100633_bib58","doi-asserted-by":"crossref","first-page":"2220","DOI":"10.1056\/NEJMoa1809064","article-title":"First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer","volume":"379","author":"Horn","year":"2018","journal-title":"N Engl J Med"},{"issue":"10212","key":"10.1016\/j.bj.2023.100633_bib59","doi-asserted-by":"crossref","first-page":"1929","DOI":"10.1016\/S0140-6736(19)32222-6","article-title":"Durvalumab plus platinum-etoposide versus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial","volume":"394","author":"Paz-Ares","year":"2019","journal-title":"Lancet"},{"issue":"12","key":"10.1016\/j.bj.2023.100633_bib60","doi-asserted-by":"crossref","first-page":"1823","DOI":"10.1016\/j.jtho.2020.09.009","article-title":"SCLC subtypes defined by ASCL1, NEUROD1, POU2F3, and YAP1: a comprehensive immunohistochemical and histopathologic characterization","volume":"15","author":"Baine","year":"2020","journal-title":"J Thorac Oncol"},{"issue":"5","key":"10.1016\/j.bj.2023.100633_bib61","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1001\/jamaoncol.2020.8072","article-title":"Current treatment strategies and future directions for extrapulmonary neuroendocrine carcinomas: a review","volume":"7","author":"Stelwagen","year":"2021","journal-title":"JAMA Oncol"},{"issue":"5","key":"10.1016\/j.bj.2023.100633_bib62","doi-asserted-by":"crossref","first-page":"645","DOI":"10.1016\/S1470-2045(20)30068-1","article-title":"Lurbinectedin as second-line treatment for patients with small-cell lung cancer: a single-arm, open-label, phase 2 basket trial","volume":"21","author":"Trigo","year":"2020","journal-title":"Lancet Oncol"},{"issue":"3","key":"10.1016\/j.bj.2023.100633_bib63","doi-asserted-by":"crossref","first-page":"231","DOI":"10.2217\/fon-2018-0597","article-title":"ATLANTIS: a Phase\u00a0III study of lurbinectedin\/doxorubicin versus topotecan or cyclophosphamide\/doxorubicin\/vincristine in patients with small-cell lung cancer who have failed one prior platinum-containing line","volume":"15","author":"Farago","year":"2019","journal-title":"Future Oncol"},{"issue":"4","key":"10.1016\/j.bj.2023.100633_bib64","doi-asserted-by":"crossref","DOI":"10.15252\/emmm.202114841","article-title":"Promoters of ASCL1- and NEUROD1-dependent genes are specific targets of lurbinectedin in SCLC cells","volume":"14","author":"Costanzo","year":"2022","journal-title":"EMBO Mol Med"},{"issue":"16","key":"10.1016\/j.bj.2023.100633_bib65","doi-asserted-by":"crossref","first-page":"1594","DOI":"10.1200\/JCO.2017.76.6915","article-title":"Phase I study of ATR inhibitor M6620 in combination with topotecan in patients with advanced solid tumors","volume":"36","author":"Thomas","year":"2018","journal-title":"J Clin Oncol"},{"issue":"17","key":"10.1016\/j.bj.2023.100633_bib66","doi-asserted-by":"crossref","first-page":"4002","DOI":"10.1002\/cncr.33048","article-title":"Biomarker-driven phase 2 umbrella trial study for patients with recurrent small cell lung cancer failing platinum-based chemotherapy","volume":"126","author":"Park","year":"2020","journal-title":"Cancer"},{"issue":"37","key":"10.1016\/j.bj.2023.100633_bib67","doi-asserted-by":"crossref","first-page":"15030","DOI":"10.1073\/pnas.1205943109","article-title":"Putative DNA\/RNA helicase Schlafen-11 (SLFN11) sensitizes cancer cells to DNA-damaging agents","volume":"109","author":"Zoppoli","year":"2012","journal-title":"Proc Natl Acad Sci U S A"},{"issue":"1","key":"10.1016\/j.bj.2023.100633_bib68","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1038\/s41467-021-27609-6","article-title":"EZH2 depletion potentiates MYC degradation inhibiting neuroblastoma and small cell carcinoma tumor formation","volume":"13","author":"Wang","year":"2022","journal-title":"Nat Commun"}],"container-title":["Biomedical Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417023000707?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2319417023000707?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,6]],"date-time":"2025-11-06T09:13:03Z","timestamp":1762420383000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2319417023000707"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,10]]},"references-count":68,"journal-issue":{"issue":"5","published-print":{"date-parts":[[2023,10]]}},"alternative-id":["S2319417023000707"],"URL":"https:\/\/doi.org\/10.1016\/j.bj.2023.100633","relation":{},"ISSN":["2319-4170"],"issn-type":[{"value":"2319-4170","type":"print"}],"subject":[],"published":{"date-parts":[[2023,10]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Small cell neuroendocrine carcinoma of the cervix: From molecular basis to therapeutic advances","name":"articletitle","label":"Article Title"},{"value":"Biomedical Journal","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.bj.2023.100633","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier B.V. on behalf of Chang Gung University.","name":"copyright","label":"Copyright"}],"article-number":"100633"}}